Why Fortrea Holdings Inc.’s (FTRE) Stock Is Down 11.28%
As of Thursday, October 29, Fortrea Holdings Inc.’s FTRE share price has dipped by 11.28%, which has investors questioning if this is right time to buy.Jenna Brashear
Stock Evaluator: Fortrea Holdings Inc. (FTRE)
Fortrea Holdings Inc. FTRE
$23.14
-2.75
-10.61%
October 29, 2026 4:00:00 PM
EST
Volume: 4,952,556
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Life Sciences Tools & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
Commentary & Analysis
Why Fortrea Holdings Inc.’s (FTRE) Stock Is Up 5.44%
As of Wednesday, October 28, Fortrea Holdings Inc.’s FTRE share price has surged by 5.44%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Which Is a Better Investment, Fortrea Holdings Inc. or Repligen Corporation Stock?
Learn more about whether Fortrea Holdings Inc. or Repligen Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Michael Rose
Which Is a Better Investment, Bio-Rad Laboratories, Inc. or Fortrea Holdings Inc. Stock?
Learn more about whether Bio-Rad Laboratories, Inc. or Fortrea Holdings Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Jenna Brashear
Which Is a Better Investment, Fortrea Holdings Inc. or 10x Genomics, Inc. Stock?
Learn more about whether Fortrea Holdings Inc. or 10x Genomics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Michael Rose
Financial Summary
| Share Statistics | FTRE | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,461.2 | $3,732.9 | 58% |
|
| Shares Out (Mil) | 94.8 | 105.4 | 61% |
|
| Institutional Ownership | 98.9% | 88.3% | 83% |
|
| Float (Mil) | 94.0 | 79.7 | 59% |
|
| Beta | 1.95 | 1.19 | 91% |
|
| Avg Daily Volume (000s) | 2,090 | 960 | 82% |
|
| Price Change (52-week) |
149.1% | 90.9% | 97% |
|
| Growth | FTRE | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 1.1% | 7.6% | 21% |
|
| Net Income (5yr) | (22.4%) | (11.2%) | 18% |
|
| EPS (5yr) | na | 2.5% | na |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.0%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 12 | 12 | 13 | |
| Current EPS | $0.217 | $0.846 | $1.131 | |
| Month Ago EPS | $0.211 | $0.840 | $1.139 | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | $0.209 | $0.827 | $1.124 | |
| Year/Year Chg | (256.1%) | (107.8%) | (113.1%) | |
| Financials | FTRE | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $2,677 | $800 | 65% |
|
| Net Income (TTM) (Mil) | ($85) | ($32) | 12% |
|
| EPS (TTM) | ($0.915) | ($0.300) | 22% |
|
| Operating Cash Flow (TTM) (Mil) | $228 | $47 | 61% |
|
| Net Cash Flow (TTM) (Mil) | na | $14 | na |
|
| Long-Term Debt (Q1) (Mil) | $1,092 | $284 | 67% |
|
| Enterprise Value (Q1) (Mil) | $2,853 | $3,582 | 54% |
|
| Valuation | FTRE | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.70 | 3.70 | 78% |
|
| P/E | na | 38.7 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 6.7 | na |
|
| Ratios | FTRE | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 19.3% | 47.7% | 20% |
|
| Net Margin | (3.2%) | (3.2%) | 27% |
|
| ROA | (3.1%) | (4.8%) | 32% |
|
| ROE | (15.3%) | (7.9%) | 25% |
|
| Liabilities to Assets | 80.7% | 41.8% | 75% |
|
| F-Score | 4 | 5 | 34% |
|
Passing Stock Screens
As of 10/28/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
Kirkpatrick Bargain Screen
Factors: Value, Momentum
Investing model outlined in Charles Kirkpatrick's book, Beat the Market: Invest by Knowing What Stocks to Buy and What Stocks to Sell.
| Performance Since Inception: | 6.8% |
| +/- S&P 500: | -0.7 |
GURU STRATEGY
O'Shaughnessy: Growth Screen II
Factors: Value, Momentum
O'Shaughnessy tries to predict the future using historical long-term trends.
| Performance Since Inception: | 14.9% |
| +/- S&P 500: | +7.4 |
